Sanofi Pasteur, a Sanofi Company
sanofi.comTotal trials
374
Active
15
Phase 3
142
Total enrollment
2,162,897
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 31 of 31 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine | — | — | — | — | — | 2 | |
| RotaTeq | — | — | — | — | — | 2 | |
| PCV21 vaccine | — | — | — | — | — | 1 | |
| Prevnar 20 vaccine | — | — | — | — | — | 1 | |
| M-M-R II vaccine | — | — | — | — | — | 1 | |
| Vaxelis vaccine | — | — | — | — | — | 1 | |
| Varivax | — | — | — | — | — | 1 | |
| Hexaxim Vaccine | — | — | — | — | — | 1 | |
| PCV21 | — | — | — | — | — | 1 | |
| 20vPCV | — | — | — | — | — | 1 | |
| Yellow fever vaccine | — | — | — | 5 | |||
| Acne mRNA vaccine | — | — | — | — | — | 2 | |
| MenACYW conjugate vaccine | — | — | — | 8 | |||
| Pneumococcal 13-valent Conjugate Vaccine | — | — | — | — | 6 | ||
| Rotavirus vaccine | — | — | — | — | 5 | ||
| Meningococcal group B vaccine | — | — | — | 5 | |||
| Quadrivalent Influenza Standard Dose Vaccine | — | — | — | — | — | 4 | |
| Pentavalent Meningococcal ABCYW vaccine | — | — | — | — | — | 2 | |
| Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 | — | — | — | — | — | 1 | |
| TIV mRNA-neuraminidase | — | — | — | — | — | 1 | |
| TIV mRNA-HA Vaccine 2 | — | — | — | — | — | 1 | |
| Quadrivalent Influenza Vaccine High Dose | — | — | — | — | — | 1 | |
| Paracetamol | — | — | — | — | — | 1 | |
| DTap-HepB-IPV-Hib vaccine | — | — | — | — | — | 1 | |
| Investigational hMPV/RSV vaccine | — | — | — | — | — | 1 | |
| Investigational hMPV vaccine | — | — | — | — | — | 1 | |
| Investigational RSV vaccine | — | — | — | — | — | 1 | |
| Licensed RSV Vaccine | — | — | — | — | — | 1 | |
| Investigational RSV+hMPV vaccine | — | — | — | — | — | 1 | |
| Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | — | — | — | 10 | |||
| Dengue Tetravalent Vaccine, Live | — | — | — | — | — | 1 |
Next readouts
- 2022-05-23
- 2022-06-24
- 2023-03-09
- 2026-04-16
- 2026-12-01
- 2027-01-18
- 2027-05-17
- 2027-05-17
- 2028-05-18
- 2028-11-30
Top conditions
- Influenza94
- Diphtheria56
- Pertussis51
- Tetanus50
- Meningitis39
- Poliomyelitis27
- Hepatitis B26
- Healthy Volunteers26
Frequently asked questions about Sanofi Pasteur, a Sanofi Company
- How many clinical trials does Sanofi Pasteur, a Sanofi Company have on ClinicalTrials.gov?
- Sanofi Pasteur, a Sanofi Company is listed as the lead sponsor on 374 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sanofi Pasteur, a Sanofi Company's trials are in Phase 3?
- 142 of Sanofi Pasteur, a Sanofi Company's trials are in Phase 3, spread across 31 active drug programs.
- What therapeutic areas does Sanofi Pasteur, a Sanofi Company focus on?
- Sanofi Pasteur, a Sanofi Company's most-studied conditions on ClinicalTrials.gov are Influenza, Diphtheria, Pertussis, Tetanus, Meningitis.
- When are Sanofi Pasteur, a Sanofi Company's next clinical trial readouts?
- Sanofi Pasteur, a Sanofi Company has 10 upcoming primary-completion readouts tracked here; the soonest is “Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia”, expected around 2022-05-23.